CDK2 and cyclin E knockout mice: Lessons from breast cancer

Trends in Endocrinology and Metabolism

Volumn 15, Issue 1, 2004, Pages 1-3

  Lents, Nathan H ^a   Baldassare, Joseph J ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E; GENE PRODUCT; CYCLIN DEPENDENT KINASE 2 INHIBITOR; ESTROGEN;

BREAST CANCER; BREAST CARCINOGENESIS; CELL CYCLE PHASE; CELL DIVISION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; CARCINOGENESIS; CELL CYCLE; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; ENZYME ACTIVITY; GENETIC ANALYSIS;

EID: 36348950898     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2003.10.011     Document Type: Short Survey

References (19)

1. Ortega S., et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35:2003;25-31.
2. Berthet, C. et al. CDK2 knockout mice are viable. Curr. Biol. DOI 10.1046/S0960982203006936.
3. Geng Y., et al. Cyclin E ablation in the mouse. Cell. 114:2003;431-443.
4. Courjal F., et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int. J. Cancer. 69:1996;247-253.
5. Keyomarsi K., et al. Deregulation of cyclin E in breast cancer. Oncogene. 11:1995;941-950.
6. Schraml P., et al. Cyclin E overexpression and amplification in human tumours. J. Pathol. 200:2003;375-382.
7. Roberts J.M., Sherr C.J. Bared essentials of CDK2 and Cyclin E. Nat. Genet. 35:2003;9-10.
8. Sage J., et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. 424:2003;223-228.
9. Ezhevsky S.A., et al. Differential regulation of retinoblastoma tumor suppressor protein by G1 cyclin-dependent kinase complexes in vivo. Mol. Cell. Biol. 21:2001;4773-4784.
10. Mittnacht S., et al. Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J. 13:1994;118-127.
11. Porter D.C., et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol. Cell. Biol. 21:2001;6254-6269.
12. Keyomarsi K., et al. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347:2002;1566-1575.
13. Span P.N., et al. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene. 22:2003;4898-4904.
14. Rudolph P., et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int. J. Cancer. 105:2003;674-680.
15. Sutherland R.L., Musgrove E.A. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 4:2002;14-17.
16. Dhillon N.K., Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene. 21:2002;4626-4634.
17. Berns A. Tumour suppressors: timing will tell. Nature. 424:2003;140-141.
18. Geisen C., Moroy T. The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein. J. Biol. Chem. 277:2002;39909-39918.
19. Kelly B.L., et al. Identification of a substrate-targeting domain in cyclin E necessary for phosphorylation of the retinoblastoma protein. Proc. Natl. Acad. Sci. U. S. A. 95:1998;2535-2540.